Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14,986 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Biweekly CHOP or THP-COP regimens in the treatment of newly diagnosed aggressive non-Hodgkin's lymphoma. A comparison of doxorubicin and pirarubicin: a randomized phase II study.
Tsurumi H, Yamada T, Sawada M, Kasahara S, Kanemura N, Kojima Y, Fukuno K, Hara T, Saio M, Takahashi T, Oyama M, Ozawa K, Takami T, Moriwaki H. Tsurumi H, et al. Among authors: takahashi t. J Cancer Res Clin Oncol. 2004 Feb;130(2):107-13. doi: 10.1007/s00432-003-0508-9. Epub 2003 Nov 27. J Cancer Res Clin Oncol. 2004. PMID: 14648210 Clinical Trial.
Serum-soluble interleukin-2 receptor (sIL-2R) is an extremely strong prognostic factor for patients with peripheral T-cell lymphoma, unspecified (PTCL-U).
Kitagawa J, Hara T, Tsurumi H, Goto N, Kanemura N, Yoshikawa T, Kasahara S, Yamada T, Sawada M, Takahashi T, Shimizu M, Takami T, Moriwaki H. Kitagawa J, et al. Among authors: takahashi t. J Cancer Res Clin Oncol. 2009 Jan;135(1):53-9. doi: 10.1007/s00432-008-0440-0. Epub 2008 Jul 1. J Cancer Res Clin Oncol. 2009. PMID: 18592269
Serum soluble Fas level determines clinical outcome of patients with diffuse large B-cell lymphoma treated with CHOP and R-CHOP.
Hara T, Tsurumi H, Goto N, Kanemura N, Yoshikawa T, Kasahara S, Yamada T, Sawada M, Goto H, Fukuno K, Kitagawa J, Yasuda I, Katsumura N, Takemura M, Takahashi T, Takami T, Moriwaki H. Hara T, et al. Among authors: takahashi t. J Cancer Res Clin Oncol. 2009 Oct;135(10):1421-8. doi: 10.1007/s00432-009-0586-4. Epub 2009 Apr 21. J Cancer Res Clin Oncol. 2009. PMID: 19381687
Phase II study of Rituximab combined with THP-COP as first-line therapy for patients younger than 70 years with diffuse large B cell lymphoma.
Hara T, Tsurumi H, Goto N, Kitagawa J, Kanemura N, Yoshikawa T, Kasahara S, Goto H, Fukuno K, Yamada T, Sawada M, Yasuda I, Katsumura N, Takahashi T, Takami T, Moriwaki H. Hara T, et al. Among authors: takahashi t. J Cancer Res Clin Oncol. 2010 Jan;136(1):65-70. doi: 10.1007/s00432-009-0637-x. J Cancer Res Clin Oncol. 2010. PMID: 19590893 Clinical Trial.
Indoleamine 2,3-dioxygenase in tumor tissue indicates prognosis in patients with diffuse large B-cell lymphoma treated with R-CHOP.
Ninomiya S, Hara T, Tsurumi H, Hoshi M, Kanemura N, Goto N, Kasahara S, Shimizu M, Ito H, Saito K, Hirose Y, Yamada T, Takahashi T, Seishima M, Takami T, Moriwaki H. Ninomiya S, et al. Among authors: takahashi t. Ann Hematol. 2011 Apr;90(4):409-16. doi: 10.1007/s00277-010-1093-z. Epub 2010 Oct 12. Ann Hematol. 2011. PMID: 20938662 Clinical Trial.
Phase II study of the tetrahydropyranyl adriamycin-cyclophosphamide, vincristine, and prednisolone regimen combined with rituximab as first-line treatment for elderly patients with diffuse large B-cell lymphoma.
Kasahara S, Hara T, Tsurumi H, Goto N, Kitagawa J, Kanemura N, Yoshikawa T, Goto H, Fukuno K, Yamada T, Sawada M, Takahashi T, Takami T, Moriwaki H. Kasahara S, et al. Among authors: takahashi t. Leuk Lymphoma. 2011 Apr;52(4):629-34. doi: 10.3109/10428194.2011.555024. Leuk Lymphoma. 2011. PMID: 21438831 Clinical Trial.
A phase II study of rituximab combined with pirarubicin-cyclophosphamide, vincristine and prednisolone regimen as first-line therapy for patients with indolent B-cell lymphoma.
Tsurumi H, Hara T, Goto N, Kitagawa J, Kanemura N, Yoshikawa T, Kasahara S, Goto H, Fukuno K, Yamada T, Sawada M, Shimizu M, Takahashi T, Takami T, Moriwaki H. Tsurumi H, et al. Among authors: takahashi t. Leuk Lymphoma. 2012 Feb;53(2):247-53. doi: 10.3109/10428194.2011.606383. Leuk Lymphoma. 2012. PMID: 21827339 Clinical Trial.
Serum soluble interleukin-2 receptor (sIL-2R) level is associated with the outcome of patients with diffuse large B cell lymphoma treated with R-CHOP regimens.
Goto N, Tsurumi H, Goto H, Shimomura YI, Kasahara S, Hara T, Yasuda I, Shimizu M, Murakami N, Yoshikawa T, Fukuno K, Takahashi T, Kito Y, Takami T, Moriwaki H. Goto N, et al. Among authors: takahashi t. Ann Hematol. 2012 May;91(5):705-714. doi: 10.1007/s00277-011-1363-4. Epub 2011 Dec 21. Ann Hematol. 2012. PMID: 22183251
Serum soluble CD27 level is associated with outcome in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone.
Goto N, Tsurumi H, Takemura M, Kanemura N, Kasahara S, Hara T, Yasuda I, Shimizu M, Yamada T, Sawada M, Takahashi T, Yamada T, Seishima M, Moriwaki H, Takami T. Goto N, et al. Among authors: takahashi t. Leuk Lymphoma. 2012 Aug;53(8):1494-500. doi: 10.3109/10428194.2012.660627. Epub 2012 Mar 1. Leuk Lymphoma. 2012. PMID: 22280534
R-THP-COP versus R-CHOP in patients younger than 70 years with untreated diffuse large B cell lymphoma: A randomized, open-label, noninferiority phase 3 trial.
Hara T, Yoshikawa T, Goto H, Sawada M, Yamada T, Fukuno K, Kasahara S, Shibata Y, Matsumoto T, Mabuchi R, Nakamura N, Nakamura H, Ninomiya S, Kitagawa J, Kanemura N, Nannya Y, Katsumura N, Takahashi T, Kito Y, Takami T, Miyazaki T, Takeuchi T, Shimizu M, Tsurumi H. Hara T, et al. Among authors: takahashi t. Hematol Oncol. 2018 Oct;36(4):638-644. doi: 10.1002/hon.2524. Epub 2018 Jun 8. Hematol Oncol. 2018. PMID: 29882279 Clinical Trial.
14,986 results
You have reached the last available page of results. Please see the User Guide for more information.